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Our whole genome sequence (WGS) pipeline was assessed for accurate prediction of antimicrobial
phenotypes. For 2316 invasive pneumococcal isolates recovered during 2015 we compared WGS pipeline
data to broth dilution testing (BDT) for 18 antimicrobials. For 11 antimicrobials categorical discrepancies
were assigned when WGS-predicted MICs and BDT MICs predicted different categorizations for sus-
ceptibility, intermediate resistance or resistance, ranging from 0.9% (tetracycline) to 2.9% (amoxicillin).
For b-lactam antibiotics, the occurrence of at least four-fold differences in MIC ranged from 0.2% (mer-
openem) to 1.0% (penicillin), although phenotypic retesting resolved 25%e78% of these discrepancies.
Non-susceptibility to penicillin, predicted by penicillin-binding protein types, was 2.7% (non-meningitis
criteria) and 23.8% (meningitis criteria). Other common resistance determinants included mef (475
isolates), ermB (191 isolates), ermB þmef (48 isolates), tetM (261 isolates) and cat (51 isolates). Additional
accessory resistance genes (tetS, tet32, aphA-3, sat4) were rarely detected (one to three isolates). Rare
core genome mutations conferring erythromycin-resistance included a two-codon rplD insertion
(rplD69-KG-70) and the 23S rRNA A2061G substitution (six isolates). Intermediate cotrimoxazole-
resistance was associated with one or two codon insertions within folP (238 isolates) or the folA I100L
substitution (38 isolates), whereas full cotrimoxazole-resistance was attributed to alterations in both
genes (172 isolates). The two levoﬂoxacin-resistant isolates contained parC and/or gyrA mutations. Of 11
remaining isolates with moderately elevated MICs to both ciproﬂoxacin and levoﬂoxacin, seven con-
tained parC or gyrAmutations. The two rifampin-resistant isolates contained rpoBmutations. WGS-based
antimicrobial phenotype prediction was an informative alternative to BDT for invasive pneumococci.
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d/4.0/).[1,2]. The distributions of both pneumococcal serotypes and sus-
ceptibility proﬁles are subject to rapid ﬂuctuations in response to
the current highly effective conjugate vaccines that target strains of
speciﬁc serotypes. Capsular serotyping is of critical importance for
evaluating the effectiveness of current vaccines and for generating
serotype distribution data that could prove useful for formulating
next-generation vaccines. Accurate determination of antimicrobial
susceptibility is important both for immediate treatment of pa-
tients and for formulating general treatment guidelines for pneu-
mococcal disease [2]. An automated whole genome sequencelogy and Infectious Diseases. This is an open access article under the CC BY-NC-ND
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detailed identiﬁcation of genotypes and characteristics such as
surface protein antigens [1]. Theoretically, all strain phenotypes can
be deduced from a single permanent WGS record. Obtaining key
pneumococcal parameters through an automated bioinformatics
pipeline ensures that all deduced features are linked to the same
pneumococcal culture. Automated extraction of these features from
WGS obviates much of the specialized technical skills and labour
required for obtaining these phenotypes conventionally. Here we
show results of a WGS bioinformatics pipeline predicting antimi-
crobial phenotypes, and compare these predictions with pheno-
typic testing of 2316 year 2015 invasive pneumococcal disease (IPD)
isolates.
Materials and methods
Isolates
A convenience sampling of 2316 consecutive IPD isolates
collected through Active Bacterial Core surveillance (ABCs), and
representing approximately 82% of projected year 2015 cases, were
subjected to WGS. The surveillance population is described and
detailed depictions of IPD disease rates in the USA during the
period 1998e2015 are provided at http://www.cdc.gov/
pneumococcal/surveillance.html. The year 2015 IPD rates shown
at this site include cases represented by the causal isolates that we
describe in this study. Additionally, 738 of the year 2015 isolates
used for our study presented here were among 2528 isolates pre-
viously employed for correlating b-lactam antibiotic MICs to
penicillin-binding protein (PBP) types [3].
Whole genome sequencing
Streptococcus pneumoniae strains were cultured on Trypticase
soy agar supplemented with 5% sheep blood and incubated over-
night at 37C in 5% CO2. Genomic DNA for short-read WGS was
extractedmanually using amodiﬁed QIAamp DNAmini kit protocol
(Qiagen, Inc., Valencia, CA, USA). Nucleic acid concentration was
quantiﬁed by an Invitrogen Qubit assay (Thermo Fisher Scientiﬁc
Inc., Waltham, MA, USA) and samples were sheared using a Covaris
M220 ultrasonicator (Covaris, Inc., Woburn, MA, USA) programmed
to generate 500-bp fragments. Libraries were constructed on the
SciCloneG3 (PerkinElmer Inc., Waltham, MA, USA) using a TruSeq
DNA PCR-Free HT library preparation kit with 96 dual indices
(Illumina Inc., San Diego, CA, USA) and quantiﬁed by a KAPA qPCR
library quantiﬁcation method (Kapa Biosystems Inc., Wilmington,
MA, USA). WGS was generated employing two MiSeq instruments
and the MiSeq v2 500 cycle kit (Illumina Inc).
Conventional MIC determinations
All 2316 isolates were subjected to broth dilution testing (BDT)
for determination of MICs and compared with WGS-based pre-
dictions. Wells containing both erythromycin and clindamycin
detected inducible clindamycin-resistance as previously described
[4]. Discordant results where WGS-based predictions differed from
BDT by two or more dilutions (at least four-fold MIC differences)
were retested using Etests as described by the manufacturer (Bio-
merieux, Marcy l’Etoile, France) or D testing as previously described
[5]. True discrepancies were those results where both agar
diffusion-based retesting (Etests or D tests) and the original BDT
results were in agreement and disagreed with WGS-based pre-
dictions. Categorical discrepancies were deﬁned as BDT-generated
MICs predictive of susceptibility, intermediate resistance orresistance according to established MIC cut-offs [5] that differed
from WGS-based predictions for these three categories.
b-lactam antibiotic MICs
PBP types, based upon PBP1a, PBP2b and PBP2x transpeptidase
amino acid sequences, were generated for each isolate as previ-
ously described [1]. The most frequently encountered conventional
MICs for the six antibiotics previously associated with a PBP type,
even if previously encountered only once, were assigned for each
PBP type. PBP types (including individual protein sequences) and
MIC correlates for each PBP type are periodically updated at http://
www.cdc.gov/streplab/mic-tables.html. At this website we also
record the frequencies of each PBP type and associated MICs for b-
lactams. Resistance, intermediate resistance and susceptibility
(both non-meningitis and meningitis criteria) employed previously
established MIC cut-offs [5]. Categorical discrepancies employed
both non-meningitis and meningitis criteria.
Non-b-lactam-resistance determinants
The sequence queries used and bioinformatics pipeline for
detection of resistance determinants are provided in a previous
study [1], with modiﬁcations periodically added at https://github.
com/BenJamesMetcalf/Spn_Scripts_Reference. Additionally, the
ARG-ANNOT database was employed [6]. A commonly encountered
query for identiﬁcation of a putative inactivating missense muta-
tion within ermB was added to the pipeline (TTGGAACAGGTAAA-
GAGCATTTAACGACGA), where the underlined base indicates a G to
A change at base 134 resulting in a glycine to glutamate
substitution.
Clonal complex determination
As previously described [1], clonal complexes were loosely
deﬁned as sharing four or more alleles with a given reference
multilocus sequence type (ST). Reference STs were chosen accord-
ing to abundance within a given serotype and/or their presence
withinmultiple serotypes of the study, and differed by at least three
alleles from other clonal complex reference STs.
Fastq ﬁle accession
Accession information for the 2316 fastq ﬁles used in this work
are provided in the Supplementary material (Table S1).
Results
PBP types among year 2015 IPD isolates
Of the 2316 isolates for which PBP-type-based MIC predictions
[1,3] and conventional MICs were compared, 104 (4.5%) were not
used for b-lactam antibiotic MIC predictions because their PBP
types were newly encountered and not previously associated with
conventional MIC testing results. The WGS data from seven addi-
tional isolates had assembly errors preventing the generation of a
PBP type.
PBP-based predictions of wild-type susceptibility to b-lactam
antibiotics
Among the 1680 isolates with WGS-based penicillin MIC of
0.03, there were 12 discrepancies (0.7%) between WGS-based
predictions and BDT testing (Table 1). For the purpose of this
analysis, eight were considered potential categorical discrepancies,
Table 1
Comparison of penicillin MICs predicted by whole genome sequence pipeline penicillin-binding protein types to broth dilution testing MICs
Predicted penicillin MIC (n) No. BDT
discrepancies (MIC)a,b
CDs No. with 2
dilution
differences
Retests of 2 dilution differences. No of
PBP types
No of clonal
complexes
Agree with
WGS
prediction
True
discrepancya
0.03 (1680) 4 (0.06) 8 8 8 0 89 123
3 (0.12)
3 (0.25)
2 (2.0)
¼ 0.06 (44) 12 (0.03) 5 0 NA NA 8 9
5 (0.12)
¼0.12 (35) 9 (0.06) 10 0 NA NA 7 6
1 (0.25)
¼0.25 (201) 3 (0.03) 5 5 5 0 13 6
2 (0.06)
12 (0.12)
16 (0.5)
¼0.5 (33) 3 (0.25) 0 0 NA NA 5 3
2 (1.0)
¼ 1.0 (33) 14 (0.5) 0 0 NA NA 6 7
2 (2.0)
¼ 2.0 (116) 19 (1.0) 10 6 4 2 (0.25,0.5) 7 5
8 (4.0)
2 (8.0)
2 (0.5)
2 (0.25)
¼ 4.0 (55) 8 (2.0) 17 4 0 4 (0.5, 1.0, 0.25) 7 7
5 (8.0)
2 (0.5)
1 (1.0)
1 (0.25)
¼ 8 (8) 4 (4.0) 4 0 NA NA 3 2
Totals (%, 95% CI
2205 (100%, NA)
147 (6.7%, 5.7%e7.8%) 59 (2.7%,
2.0%e3.4%)
23 (1.0%,
0.66%e1.6%)
17 6 (0.27%, 0.10%e0.59%) 145
BDT, broth dilution testing; PBP, penicillin-binding protein; WGS, whole genome sequence.
a The discordant BDT result(s) in parentheses.
b Categorical discrepant BDT results are in bold. These apply for both meningitis and non-meningitis guidelines [3]. Instances of at least four-fold MIC differences (two
dilutions) between BDT result and WGS prediction are underlined.
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though all eight of these isolates were from non-meningitis cases
(data not shown). Since all eight of these categorical discrepancies
had actual BDT MICs of at least two dilutions more than the pre-
dicted MIC of 0.03 mg/L, they were retested using conventional
agar diffusion methodology (Etests). The eight isolates were in
agreement with theWGS prediction, since they yielded MICs in the
range of 0.012e0.032 mg/L (data not shown). Similar results were
found for the other ﬁve b-lactam antibiotics (see Supplementary
material, Tables S2 to S6) in that when PBP proﬁles were indica-
tive of little or no decreased susceptibility, no true discrepancies
were observed. The lowest BDT MIC was obtained for 75.7%e89.5%
of the 2205 isolates for the six different b-lactam antibiotics
(Table 1, and see Supplementary material, Tables S2 to S6). There is
a lower number of clonal complexes within resistant PBP types
thanwithin PBP types that predict basal susceptibility (Table 1, and
see Supplementary material, Tables S2 to S6). reﬂecting the pre-
ponderance and greater genetic diversity of basally susceptible
pneumococcal strains (data not shown). The majority of true dis-
crepancies for the six b-lactam antibiotics reﬂected isolates with
lower MICs than those predicted by PBP type correlates (Table 1,
and see Supplementary material, Tables S2 to S6).
WGS-based predictions for erythromycin, clindamycin and
quinupristin-dalfopristin
Almost all macrolide resistance was detected through a query
that broadly detectsmef genes [1,7,8] and ermB [1,9,10]. BDT testing
results indicated that in about 5% of ermB-positive isolates,clindamycin-resistance was inducibly expressed rather than
constitutively (data not shown). Also included in the pipeline is a
putative inactivating (null) missense mutation within ermB (pro-
vided in methods) that we have identiﬁed fairly frequently
(representative isolate 20155282).We correctly predicted complete
erythromycin and clindamycin susceptibility for 17 such isolates
based upon this speciﬁc pipeline query sequence. There were two
true discrepancies for ermB-positive isolates. Both strains contained
full-length ermB structural gene alleles (isolates 20156290 and
20161788) that we have previously observed within isolates resis-
tant to erythromycin and clindamycin (data not shown).
Three true discrepancies were observed among the 48 isolates
positive for both ermB andmef (Table 2). Two of these isolates were
also unexpectedly non-susceptible to quinupristin-dalfopristin
(BDT MIC of >1 mg/L veriﬁed with subsequent Etest results of
2e3 mg/L (isolates 20154278 and 20155427). Another isolate pos-
itive for the pipeline ermB query was clindamycin-susceptible and
was retrospectively found to contain a truncated ermB gene due to a
premature stop codon at base 642 of the 735-bp structural gene
(isolate 20155328). The 23S rRNA gene A2061G substitution pre-
dicted constitutive resistance to erythromycin and clindamycin
(clindamycin MIC of 1 mg/L) in four isolates, as previously observed
[11,12]; however, one isolate was only intermediately clindamycin-
resistant. Single occurrences of two isolates with 23S rRNA gene
substitutions (C2049T or A2069G) other than the resistance-
conferring A2061G substitution shown (Table 2) were susceptible
to erythromycin and other ribosome-targeting antibiotics.
One isolate with a previously observed two codon insertion
within rplD (isolate 20153241) (Table 2), a mutation previously
Table 2
Macrolide-resistance determinants and corresponding phenotype predictions compared with BDT testing results of 2316 IPD isolates
WGS result (no. isolates) interpretation c BDT discrepant result (n) Re-test result
Agreed with WGS True discrepancies
ermB (191) a eryR cliR QP-S linS eryS cliS (3) 2 1
eryR cliS (2) 2 0
eryI cliS (1) 0 1
ermB þ mef (48) eryR cliR QP-S eryR cliR QP-NS (2) 0 2
eryR cliS (1) 0 1
mef (475)b eryR cliS eryS (3) 3 0
eryR cliR (2) 2 0
rRNA A2061G (5) eryR cliR QP-S eryR cliR QP-NS (1) 1 0
eryR cliI (1)b ND ND
rplD 2 codon insertion (KG) between codons
69 and 70 (1)
eryI QP-R eryR QP-S (1) 0 1
Negative
(1597)
eryS cliS eryR (3) 2 1d
eryI (3) 3 0
eryR cliI (2) 1 1 d
Totals (%, 95% CI) (2316, 100%, NA) 25 (1.1%, 0.70%e1.6%) 15 (0.7%, 0.36%e1.1%) 9 (0.4%, 0.18%e0.74%)
BDT, broth dilution testing; IPD, invasive pneumococcal disease; WGS, whole genome sequence.
a Seventeen of these isolates were eryS cliS apparently due to a missense substitution (G41E) within the ermB structural gene that is detected by the WGS pipeline. These
isolates are not listed in the interpretation of discrepant results.
b The single discrepant intermediately clindamycin-resistant result differed from the other four by a single dilution (clindamycin MIC ¼ 0.5 rather than 1.0).
c Abbreviations: eryS and R, erythromycin-susceptible and resistant; QP-S and R, quinupristin-susceptible and resistant; cliR and S.
d Isolate was found to be inducibly clindamycin-resistant using the double disc diffusion test.
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tance to quinupristin-dalfopristin [12], was subsequently Etested as
erythromycin-resistant (MIC of 16 mg/L) and quinupristin-
dalfopristin-susceptible (MIC of 1 mg/L). Six isolates with the ri-
bosomal protein L4 (rplD) E30K substitution (including isolates
20151636 and 20153922), an alteration previously associated with
macrolide-resistance [8] or combined resistance to macrolides and
quinupristin-dalfopristin [12], were susceptible to both antimi-
crobials (data not shown). A single instance of the rplD Q67K sub-
stitution was found in an isolate that was susceptible to all
antibiotics on the BDT panel, although a strain with the two sub-
stitutions Q67R and R72G has been associated with resistance to
quinupristin-dalfopristin and linezolid [12]. We found no instances
of linezolid-resistance. Of 1597 isolates that were not predicted by
the WGS pipeline to be resistant to erythromycin, clindamycin and
quinupristin-dalfopristin, we found two isolates that were eryth-
romycin non-susceptible and inducibly clindamycin-resistant
(isolates 20154490, 20154507), suggesting a possible undetected
determinant of the erm (23S rRNA methylase) class [10e13].Cotrimoxazole (trimethoprim/sulfamethoxazole)-resistance
The folA I100L substitution [14] or one or two codon insertions
within folP [15], were highly associated with intermediate resis-
tance to trimethoprim/sulfamethoxazole (MIC of 1/19 to 2/38mg/L)
as determined by BDT (221 of 276 isolates, 80.1%) (Table 3). The
majority of the discrepancies (29/45, 64%) where single mutants in
folA or folP were not intermediately resistant was due to the BDT
MIC result of 0.5/9.5 mg/L, which is the highest MIC categorized as
cotrimoxazole-susceptible [5]. Of the 2004 year 2015 ABCs isolates
that were determined as cotrimoxazole-susceptible through BDT,
only 109 (5.4%) had an MIC of 0.5/9.5 mg/L. In this study we
determined that of 101 isolates with cotrimoxazole MICs of 0.5/
9.5 mg/L, 16 (15.8%) contained folP insertions and 13 (12.8%) con-
tained the folA I100L substitution. Double mutants with the folA
I100L substitution and a folP one or two codon insertion accounted
for 172 isolates, the majority (163/172, 94.8%) of which were fully
cotrimoxazole-resistant (Table 3). We found nine different one or
two codon insertions between codons 59 and 69 of the 351 codon
folP gene (Fig. 1), each identiﬁed by different pipeline designationsbased upon the location of the insertion within folP and also
inﬂuenced by localized sequence divergence of immediate ﬂanking
region (not shown) due to the apparent mosaicism we observed
within many of the mutant folP alleles (data not shown). With the
exception of folP insertions 188 and 176, these one or two amino
acid insertions have been previously identiﬁed in pneumococci
resistant to sulfonamides or cotrimoxazole [15e17].Tetracycline resistance
Eight of the 261 tetM-positive isolates were found to be
tetracycline-susceptible, potentially indicating a defective tetM
gene (Table 4). Two tetM-positive isolates were additionally tetS-
positive [18,19] (isolates 20152656 and 20156655) and one isolate
negative for tetracycline-resistance according to our original
pipeline [1] contained tet32 [20] alone (isolate 20153228). The tetS
and tet32 determinants were detected solely through the ARG-
ANNOT database [6] that we have added to our pipeline. Both
tetS and tetMwere identiﬁed through the ARG-ANNOT database for
isolates 20152656 and 20156655, whereas only tetM was detected
for these two isolates through our 100-bp pipeline query. This
indicated that the positive ARG-ANNOT pipeline results could have
been due to the presence of two different tetracycline-resistance
genes that share 70% identity over a 70% structural gene over-
lap [6], or could have been due to the presence of a single some-
what divergent tetM allele that has localized high sequence identity
to our tetM pipeline query. We found that the latter circumstance
was true, with the two full-length structural genes from the two
isolates sharing 96.0%e96.1% and 78.2%e78.3% sequence identity to
the ARG-ANNOT tetM (1920 bp) and tetS (1926 bp) database se-
quences, respectively.
One tetracycline-resistant isolate (isolate 20152918) tested
negative for resistance genes in our pipeline and in the ARG-ANNOT
database.Chloramphenicol resistance
All cat-positive [21] isolates were chloramphenicol-resistant
with no associated BDT discrepancies (see Supplementary
material, Table S7). Of the 2265 cat-negative isolates, there were
Table 3
Determinants of cotrimoxazole resistance and corresponding phenotype predictions compared to BDT testing results of 2316 IPD isolates
Cotrimoxazole resistance
determinants
(no. of occurrences)
Predictiona BDT discrepant result (n) Retest result for >2 dilution discrepancy
Agrees with WGS True discrepancy
folP insertion (238) Cot-I (MIC 1.0e2.0 mg/L) 0.5 mg/L (16) NA NA
>4 mg/L (5) 3 2a
¼4 mg/L (6) NA NA
folA I100L (38) Cot-I (MIC 1.0e2.0 mg/L) 0.5 mg/L (13) NA NA
0.25 mg/L (1) 0 1
4 mg/L (1) NA NA
>4 mg/L (3) 2 1 b
folP insert þ folA I100L (172) Cot-R (MIC 4.0 mg/L) 1e2 mg/L (8) NA NA
1 mg/L (1) 0 1c
Negative (1868) Cot-S (MIC 0.5 mg/L) 1 mg/L (7) 7 0
2 mg/L (3) 3 0
4 mg/L (2) 2 0
Totals (%, 95% CI)
(2316, 100%, NA)
66 (2.8%, 2.2%e3.6%) 17 5 (0.22%, 0.07%e0.5%)
BDT, broth dilution testing; IPD, invasive pneumococcal disease; WGS, whole genome sequence.
a MICs shown correspond to cotrimoxazole (trimethoprim/sulfamethoxazole) MICs of 0.5/9.5 to >4/76 mg/L.
b Etest MIC of 3 mg/L for two of these three isolates. For one of the two folP insertion isolates the Etest MIC was >32 mg/L.
c Etest MIC of 1.5 mg/L for this isolate.
Fig. 1. One and two codon insertions within localized region of folP between codons 59 and 69, their designations, and number of isolates detected with insertion. aContain no
insertions within indicated region; however, sequence not examined.
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to be chloramphenicol-susceptible by Etests (MICs of 6 mg/L).
More than 50% of ABCs isolates determined to be chloramphenicol-
susceptible through BDT during 2015 had a chloramphenicol BDT
MIC of 4.0 mg/L, differing by a single dilution from the criteria for
resistance [4].
Fluoroquinolone resistance
In pneumococci and other species, ﬂuoroquinolones are most
active in targeting localized regions within the ParC subunit of DNA
topoisomerase IV and the GyrA subunit of DNA gyrase [22]. Both
levoﬂoxacin-resistant isolates identiﬁed by BDT (isolates 20160273
and 20153527) also had a ciproﬂoxacin MIC of 4 mg/L and were
associated with parC substitutions (see Supplementary material,
Table S8). One of these two strains additionally contained the gyrA
S81Y substitution and was the only double mutant identiﬁed.
Although there are no CLSI guidelines for pneumococcal ciproﬂox-
acin MICs [5], we considered MICs of 4 mg/L found among 12
isolates (see Supplementarymaterial, Table S8) to be phenotypically
signiﬁcant and potentially associated with causal genomic alter-
ations. Although levoﬂoxacin-resistance is considered to be4mg/
L, we also considered the levoﬂoxacin MIC of 2 mg/L as moderately
elevated, since only 38 of the 2316 isolates had levoﬂoxacin MICs of
2mg/L. Of the nine levoﬂoxacin-susceptible isolates with elevated
MICs to both ﬂuoroquinolones (see Supplementary material,
Table S8), ﬁve contained substitutions within ParC or GyrA, all of
which have been associated with elevated MICs to these antibiotics[23]. Although our pipeline successfully detected the two
levoﬂoxacin-non-susceptible isolates in our isolate set, there were
six instances of elevated ciproﬂoxacinMICs (ﬁvewithMIC of 4mg/L
and one with MIC >4 mg/L) that were not detected (isolates
20154278, 20154285, 20153966, 20155459, 20160446, 20161660).
Rifampin resistance
Rifampin binds to the b-subunit of bacterial RNA polymerase to
prevent its essential function [24]. Two rifampin-resistant isolates
(isolates 20160910 and 20153860) were ﬂagged by the pipeline,
each showing a single substitution (H499N or D489V) within rpoB
previously associated with rifampin-resistance [25,26]. Retesting
(Etests) of these isolates revealed a rifampin MIC of 8.0 mg/L for the
H499N substitution, and an MIC of >32 mg/L for the D489V sub-
stitution (see Supplementary material, Fig. S1). Ten additional
substitutions within this region of RpoB were ﬂagged in one or two
isolates, but were associated with rifampin-susceptibility (BDT MIC
of 2 mg/L and Etest results of 0.05 mg/L), including S481L,
M488I, M488V, D489N, H491P, H491R, H491Y, N492T, S495C and
H499L. Of the 12 substitutions, all present as single RpoB sub-
stitutions, only the D489N and H499L substitutions were previ-
ously associated with pneumococcal rifampin-resistance [25,26].
Vancomycin
We did not detect any isolates that were positive for the
vancomycin-resistance determinant queries in our pipeline and in
Table 4
Determinants of tetracycline resistance and corresponding phenotype predictions compared with BDT testing results of 2316 IPD isolates
WGS data (no. occurrences) Prediction BDT discrepant results (No) Re-test result for 2-fold dilution discrepancy
Agrees with WGS Agrees with BDT
tetM (259) Tet-R
(MIC 4)
0.5 (10) 2 8
2.0b (4) ND ND
(tetM þ tetS)a (2) Tet-R None
tet32 (1) Tet-R None
Negative (2054) Tet-S 4 (7) 5 2
Totals (%, 95% CI) (2316, 100%, NA) 21 (0.91%, 0.56%e1.4%) 8 (0.35%, 0.15%e0.68%) 9 (0.4%, 0.18%e0.74%)
BDT, broth dilution testing; IPD, invasive pneumococcal disease; WGS, whole genome sequence.
a Single tetracycline-resistance determinant within both isolates detected solely as tetM through CDC pipeline [1] and as both tetM and tetS through ARG-ANNOT database
[6].
b 2.0 mg/L is intermediate resistance.
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BDT vancomycin MICs of >1 mg/L, all of which were retested and
found to have MICs of 0.5 mg/L.
Aminoglycosides and streptothricins
The aphA-3 and sat4 genes, associated with resistance to kana-
mycin and streptothricins, respectively, and often co-linked to each
other or to other resistance genes on insertion elements in Gram-
positive species [9,27], were detected from the ARG-ANNOT data-
base [6] among four isolates. Two unrelated isolates (20156295 and
20153959) were positive for both determinants, along with ermB
and tetM. The third isolate (20154707) was positive only for aphA-3
and ermB. The fourth isolate (20152957) was positive for only sat4
and ermB. We did not perform phenotypic testing for kanamycin
and streptothricins.
Discussion
A signiﬁcant ﬁnding from this work was the absence of
discrepant phenotypic testing results for PBP types predictive of
wild-type susceptibility to b-lactam antibiotics. These ‘sensitive’
PBP alleles are all highly conserved with wild-type unaltered
pneumococcal PBP genes, consistent with strong associations of
altered PBPs with b-lactam non-susceptibility [1,3]. The high pro-
portion of clonal complexes relative to PBP types among b-lactam-
susceptible isolates reﬂects the broad clonal distribution of indi-
vidual ‘sensitive’ PBP alleles [1]. In contrast, the genetic diversity of
isolates with reduced susceptibility or resistance to b-lactams is
relatively constrained in the USA, especially now after sequential
introductions of two highly effective conjugate vaccines within the
past 17 years [1,2].
Most instances where at least four-fold differences between BDT
MIC and WGS-predicted MICs could not be resolved involved
decreased BDT MICs compared with pipeline-based predictions.
This is a much better scenario than, for example, underestimated b-
lactam MICs. For antibiotics such as b-lactams, this potentially re-
ﬂects compensatory changes that alleviate ﬁtness costs that occur
within PBP domains not included within the PBP type, or other
enzymes affecting peptidoglycan structure such as MurM that in
some strains are known to inﬂuence b-lactam MICs [28,29]. There
was a small number of isolates with unexplained non-susceptibility
or elevated MICs to other antibiotics, including erythromycin,
clindamycin, tetracycline and quinupristin-dalfopristin. For these
isolates, deeper searches for resistance determinants that include
expansion of the original gene query targets and identiﬁcation of
potentially new accessory genes or chromosomal mutations are
warranted and are ongoing. Conventional testing of isolates that are
ﬂagged due to detection of rare alterations within highly conserved
determinants, such as those that are involved in translation (e.g.rplD, rplV, 23S rRNA genes), transcription (e.g. rpoB) and DNA
replication (e.g. parC, gyrA), is warranted, not only due to the lack of
abundant pre-existing phenotypic data, but because of the likeli-
hood that resistance may often involve additional undetected de-
terminants that could affect resistance levels and additional
antimicrobial susceptibility phenotypes. It will be necessary to
continue BDT MIC determinations for a carefully selected signiﬁ-
cant minority of surveillance isolates to be vigilant for the suc-
cessful emergence of new resistance mechanisms. Where isolates
are actually predicted to be susceptible due to identiﬁed mutations
within known accessory element resistance genes (for example the
ermB missense substitution associated with erythromycin-
susceptible isolates described in this work), these isolates should
still be considered potentially reversibly resistant. For other anti-
microbials, WGS-based predictions might inﬂuence current
phenotypic guidelines. For example, 58% of themost recently tested
2611 ABCs isolates tested as phenotypically chloramphenicol-
susceptible had the MIC of 4 mg/L, suggesting intrinsic reduced
susceptibility that might not be compatible with assigning the MIC
of 8 mg/L as fully chloramphenicol-resistant.
The folA I100L substitution and insertions within a small region
of folP confer resistance to trimethoprim and sulfamethoxazole,
respectively [14e16]. Here we have shown that individually the folA
I100L and folA insertions are usually associated with intermediate
resistance to cotrimoxazole (trimethoprim-sulfamethoxazole)
while mutations in both genes are nearly always indicative of full
cotrimoxazole resistance. The rarity of cotrimoxazole MIC dis-
crepancies (ﬁve instances within 2316 isolates) is probably dictated
by the essential roles of mutant folA and folP alleles in the folic acid
biosynthetic pathway and the lack of othermajor genetic inﬂuences
on cotrimoxazole-resistance.
The ARG-ANNOT database [6] provides a useful expansion of our
original resistance pipeline [1] for detecting accessory genome
resistance determinants. For these 2316 isolates it identiﬁed all of
the accessory element genes among these isolates that were
detected by our pipeline (mef, ermB, tetM, cat). ARG-ANNOT also
detected a distinct tetracycline-resistance gene (tet-32) within one
isolate and potential resistance to aminoglycosides and/or strep-
tothricin antibiotics in four isolates. Although for this isolate set
ARG-ANNOT was slightly more encompassing than our own
specialized pipeline for detection of accessory element resistance
features, the potential exists for our smaller, broadly encompassing
gene queries to detect genes that are not detected through ARG-
ANNOT. For example, in groups A and B streptococci, our broadly
encompassing ermTR and mef queries (also included in our pneu-
mococcal pipeline) appear to quantitatively detect these de-
terminants; however, these two genes were not detected through
ARG-ANNOT (data not shown). We have observed that ARG-
ANNOT has invariably detected the macrolide-resistance determi-
nantmsrD [30] among themefþ streptococcal isolates that we have
B.J. Metcalf et al. / Clinical Microbiology and Infection 22 (2016) 1002.e1e1002.e81002.e7characterized through our pipelines (data not shown). Although
ARG-ANNOT was not designed to recognize signatures of re-
sistances within core genomic determinants (e.g. PBP types, folA,
folP, 23S rRNA genes, rpoB) it is useful for recognizing additional
accessory determinants among streptococci not detected through
our species-speciﬁc pipelines (manuscripts in preparation). We
conclude that our streptococcal accessory resistance pipelines and
the ARG-ANNOT database are complementary resources for
detecting accessory resistance determinants.
Here we demonstrated the capability of our WGS pipeline to
accurately and reliably predict antimicrobial testing results for
currently recovered IPD isolates to six different b-lactam antibi-
otics, erythromycin, clindamycin, cotrimoxazole, tetracycline and
chloramphenicol. In addition, the pipeline detected rare instances
of ﬂuoroquinolone-resistance and rifampin-resistance. This sam-
pling of recent national surveillance IPD isolates gives an accurate
assessment of the pipeline's reliability for detecting and measuring
individual resistance phenotypes, and for determining the fre-
quencies of different resistance mechanisms. WGS-based meth-
odology is an effective substitute for BDT that also serves for
concurrent determination of other critical pneumococcal strain
features. As technical advancements continue, WGS technology
may be employed in future clinical settings for deducing key
pathogen parameters relevant to patient care. The high concor-
dance of WGS-based predictions with pneumococcal antimicrobial
phenotypes is compatible with this goal.Acknowledgements
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